Table 1.
Consumptions of broad-spectrum antimicrobial agents at National Taiwan University Hospital during two time periods: January–June 2019 and January–June 2020
| Antibiotic | Antibiotic consumption (DDDs/1000 patient-days) by indicated time period |
% change | |
|---|---|---|---|
| January–June 2019 | January–June 2020 | ||
| β-Lactam/β-lactamase inhibitor combinations a | 372.3 | 387.6 | 4.1 |
| Extended-spectrum cephalosporins b | 763.5 | 763.7 | 0.0 |
| Quinolones c | 182.3 | 201.8 | 10.7 |
| Carbapenems d | 330.4 | 376 | 13.8 |
| Aminoglycosides e | 237 | 221.3 | –6.6 |
| Colistin | 63.3 | 78.4 | 23.9 |
| Tigecycline | 56.3 | 89.7 | 59.3 |
| Fosfomycin | 23.7 | 41.4 | 74.7 |
| Glycopeptides f | 340.1 | 384 | 12.9 |
| Linezolid | 12.1 | 15.4 | 27.3 |
| Daptomycin | 77.3 | 95.1 | 23.0 |
DDD, defined daily doses.
a
Including cefoperazone/sulbactam, piperacillin/tazobactam and ceftazidime/avibactam.
b
Including cefotaxime, cefoperazone, flomoxef, ceftazidime, ceftriaxone and cefepime.
c
Including ciprofloxacin, moxifloxacin and levofloxacin.
d
Including imipenem, meropenem, doripenem and ertapenem.
e
Including gentamicin, amikacin and streptomycin.
f
Including vancomycin and teicoplanin.